BAY1000394
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BAY1000394, covering 2013-05-03 to 2017-01-09. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies [Phase 1]